Anglicheau Dany, Suthanthiran Manikkam
Division of Nephrology, Department of Medicine and Transplantation Medicine, Weill Cornell Medical College, New York, NY 10065, USA.
Transplantation. 2008 Jul 27;86(2):192-9. doi: 10.1097/TP.0b013e31817eef7b.
Development of predictive, diagnostic, and prognostic biomarkers of allograft status and outcome is important and challenging, and may be rewarded with individualized therapy for the organ graft recipient. Herein, we summarize noninvasive messenger RNA profiling studies for ascertaining allograft status and outcome. Nucleic acid-based biomarkers of allograft status have been developed by several laboratories, but the studies have primarily been single center investigations. Ongoing multicenter trials including the Clinical Trials in Organ Transplantation (https://www.ctotstudies.org) should help further to define the clinical utility of noninvasively developed messenger RNA profiles as biomarkers of allograft status and outcome.
开发关于同种异体移植物状态和转归的预测性、诊断性和预后性生物标志物既重要又具有挑战性，而针对器官移植受者的个体化治疗可能会从中受益。在此，我们总结了用于确定同种异体移植物状态和转归的非侵入性信使核糖核酸分析研究。几个实验室已经开发出基于核酸的同种异体移植物状态生物标志物，但这些研究主要是单中心调查。正在进行的多中心试验，包括器官移植临床试验（https://www.ctotstudies.org），应有助于进一步明确非侵入性开发的信使核糖核酸谱作为同种异体移植物状态和转归生物标志物的临床效用。
